newsfilter
← Latest News
GlobeNewswire·

Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®

EWING, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has accepted its New Drug Application ("NDA") resu